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A human immunodeficiency virus type 1 (HIV-1) variant with highly reduced susceptibility to Ro 31-8959, an inhibitor of 
the viral proteinase, has been selected by repeated passage of wild-type virus in CEM cells in the presence of increasing 
concentrations of the inhibitor. Peptide sequences of the proteinase of selected virus were obtained from proviral DNA. 
Sequence comparison to wild-type (wt) proteinase demonstrated two amino acid substitutions in the resistant virus, a Gly 
to Val exchange at position 48 and a Leu to Met exchange at position 90. Furthermore, sequences of intermediate passage 
virus suggest contributions from positions 12, 36, 57, and 63 in early steps of resistance development. The selected virus 
showed a ca. 40-fold increase in 50% inhibitory concentration of Ro 31-8959. Growth kinetics of resistant virus were 
comparable to wild-type virus and the resistant genotype proved to be stable in the absence of inhibitor. Directed mutagenesis 
of the HIV-1 HXB2 proteinase at positions 48 and 90 suggested that each mutation alone led to a moderate decrease in 
sensitivity of the recombinant virus to proteinase inhibitor. However, a recombinant virus carrying both mutations in the 
proteinase gene showed a significant reduction in its sensitivity to Re 31-8959 thus proving the importance of these 
exchanges for the resistance phenotype. © 1995 Academic Press, Inc. 
INTRODUCTION 
Retroviral genomes encode an aspartyl proteinase 
whose activity is essential for processing of the gag and 
gag-po l  polyprotein precursors (Dickson et aL, 1984; 
Kr~usslich and Wimmer, 1988). The proteinase of human 
immunodeficiency virus (HIV) is part of the gag-po l  ORF 
(open reading frame) and forms active homodimers in 
assembling viral particles. Inactivation of the proteinase, 
e.g., by substitution of alanine for the catalytic aspar[ic 
acid, yields nonprocessed precursor proteins and imma- 
ture noninfectious progeny virus, as does inhibition of 
proteinase by specific inhibitors (Kohl et aL, 1988; Le 
Grice et aL, 1988; Mous et al., 1988; Seelmeier et aL, 
1988). HIV proteinase has thus been recognized as an 
attractive target for directed and specific antiviral ther- 
apy. Ro 31~8959 is such a specific inhibitor of HIV-1, 
HIV-2, and SlV proteinases (Roberts et al., 1990). It is a 
transition state mimetic based on a natural cleavage site 
with the Phe-Pro scissile bond being replaced by a hy- 
droxyethylamine moiety. Its potent and selective antiviral 
activity in chronic and acute HIV infections in vitro has 
been reported and the compound is currently undergoing 
clinical trials (Craig et aL, 1991). 
The rapid development of resistance to nucleoside or 
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nonnucleoside inhibitors of HIV reverse transcriptase 
has become a major obstacle in their clinical use as 
antiviral drugs (Larder et aL, 1989a, 1991; Rooke et al., 
1989, 1991; Land eta/., 1990; Japour etaL, 1991). A num- 
ber of mutations in the reverse transcriptase gene have 
been described which confer decreased sensitivity to 
different inhibitors or may even lead to multidrug resis- 
tance (Larder and Kemp, 1989b; Nunberg et al., 1991= 
Richman et eL, 1991; Richman, 199.2). Rapid identification 
of specific mutations underlying the development of re- 
sistance will be increasingly important to monitor ongo- 
ing therapy. It is thus of significance for new drugs to 
identify such mutations and prove their role in drug sus- 
ceptibility. We have previously selected in cell culture 
H1V-1 variants with reduced sensitivity to Ro 31-8959 and 
report here on the molecular basis of the resistant pheno- 
type (Craig et el., 1993b). 
MATERIAL AND METHODS 
Cells, virus, and select ion 
The details of cell lines, virus, and selection conditions 
have been described (Craig et aL, 1993). HIV-1 strain 
GB8 was passaged on CEM cells in the presence of 
increasing concentrations of the specific proteinase 
inhibitor Ro 31-8959 (N-tert-butyl-decahydro-2-[2(R)- 
hydroxy - 4 - phenyl - 3(S) - [IN - (2 - quinolylcarbonyl) - L - 
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asparaginyl]amino]butyl] - (4aS, 8aS) - isoquinoline - 3(S) - 
carboxamine methanesulfonate) referred to as com- 
pound XVll in Roberts etaL (1990). Virus was character- 
ized for sensitivity to each inhibitor by a syncytium reduc- 
tion assay and p24 E.LISA. 
Cos-1 cells were grown in Dulbecco's modified Eagle 
medium and MT-2 or OEM cells in RPMI 1640 medium 
(Gibco BRL), each supplemented with 10% fetal bovine 
Serum, penicillin (100 IU/ml), streptomycin (100 #g/ml), 
and glutamine (2 mM). 
PCR, cloning, and DNA sequencing 
DNA was extracted from infected cells (passage 7, 8, 
11, and 14, selection at 40, 80, 320, and 640 nM Re 
31-8959, respectively) by proteinase K digestion in the 
presence of SDS/EDTA and subsequent phenol/chloro- 
form extraction. DNA was precipitated in isopropanol, 
washed in 70% ethanol, and dissolved in TE buffer (pH 
8.0, Sambrook et aL, 1989). The viral proteinase gene 
was amplified by polymerase chain reaction (PCR, Horn 
etaL, 1985; Saiki etaL, 1988) in 50-#1 final volume in 10 
mMTris-HCI (pH 8.3), 50 mM KCI, 1.5 mM MgCI2, 0.001% 
gelatine, 2 #M of each oligonucleotide primer, 250 #M 
of each dNTP, and 5 units of Thermus aquaticus DNA 
polymerase (Ampli Taq, Perkin-Elmer-Cetus). Cycling 
conditions were as follows, 4 min/94 ° denaturation fol- 
lowed by the addition of DNA polymerase and 25 cycles 
of 40 sec/58 ° annealing, 60 sec/72 ° elongation, and 40 
sec/94 ° melting. The reaction was finished by 4 min/72 °
elongation. The oligonucleotide primers were as follows= 
Sense primer-- 5'GTCGACTAGTCAGAGCCAACAGCC- 
CCACCAGAAGAGC-- corresponding to position 1730- 
1757 of HIV-1 Bru with an Spel site added at its 5' end, 
and antisense primer--5'CAGCTGCGGCCGCTCTTC- 
TGTCAATGGCCATi-GT-FTAAC --  corresponding to posi- 
tion 2192-2217 of HIV-1 Bru with a Notl site added to 
its 5' end (Wain-Hobson et al., 1985). PCR products were 
separated on agarose gel and purified on glasmilk 
(GeneClean, Bio 101; La Jolla, CA). Purified fragments 
were digested with Spel/Notl  and ligated into a corre- 
spondingly digested and dephosphorylated pBluescript 
II SK (-)  vector (Stratagene). Plasmid DNA was prepared 
by a modified SDS/alkaline lysis method (Magic mini- 
prep, Promega) and the sequence of the insert was deter- 
mined by the dideoxy chain termination method (Seque- 
nase sequencing kit, USB) and labeling with [35S]dATP~S 
(Amersham, >37 TPq/mmol). Sequences were analyzed 
and compared using the GCG sequence analysis soft- 
ware (Genetic Computer Group, University of Wisconsin). 
The statistical significance of amino acid changes be- 
tween the wild-type and passage 11 virus was assessed 
by means of 2 x 2 contingency tables (Bailey, 1973). 
Mutagenesis of HIV-1 BRU proteinase 
The following mutations were introduced into the HIV- 
1 BRU proteinase by PCR using the appropriate mis- 
matched pairs of primers (No et al., 1989)= Gly48 -~ Val, 
Leu90 -~ Met, and the double mutant containing both 
exchanges. The mutation oligonucleotides for the 
Gly48 -~ Val exchange were BRU nucleotide position 
1968-1986 5'AAAATGATAGTGGGAA-rq-GG (sense) and 
5'CCAA]q-CCCACTATCA1-FFF (antisense) and for the 
Leu90 ~ Met exchange, Bru nucleotide position 2090- 
2111 5'GGAAGAAATCTGATGACTCAG (sense) and 5'CT- 
GAGTOATCAGAT-R-OTTCO (antisense). The mutated po- 
sitions are underlined. The flanking oligonucleotide prim- 
ers were 5~'q-FI-AGGGAAGATCTGGCC-I-rCCTAC (sense, 
BRU nucleotide position 1635-1652), encompassing the 
Bglll site at position 1641, and 5'AAGCACA-FI-GTACTG- 
ATATCTAATCCC (antisense, BRU nucleotide position 
2553-2577), encompassing the EcoRV site at position 
2578. The BglII/EcoRV fragment was inserted into a Pstl/ 
Sail fragment (nucleotide 1418-5785) of the HIV-1 HXB2 
genome which was finally introduced into a complete 
HXB2 genome (Wain-Hobson et al., 1985; Wong-Staal et 
aL, 1985). The details of the experimental strategy for the 
construction of an HXB2 clone with the Gly48 ~ Val/ 
Leu90 -~ Met double mutation will be described in detail 
elsewhere (Dean L. Winslow eta/., submitted for publica- 
tion). In brief, a full length infectious molecular clone of 
HIV-1 HXB2 was digested at the unique Ncol site and 
the two halves were subcloned into separate plasmid 
vectors. The 5' genomic fragment was further modified 
by adding a Esp31 site near the 3' end of the proteinase 
gene to make a cassette shuttle vector in which the 
wild-type proteinase coding region can be conveniently 
replaced by, e.g., mutant proteinase genes. Plasmids 
containing the 5' and 3' halves of the virus genome are 
linearized at their Ncol site, ligated, and transfected into 
MT-2 ceils to recover infectious mutant virus. 
Expression and transfection studies 
To assess the activities of the mutagenized protein- 
ases, the processing of the pol ORF in Escherichia coil 
was studied (Mous et al., 1988; Debouck et al., 1987). 
The pol ORF was isolated from the proviral clones con- 
taining the mutated proteinases by PCR (sense primer= 
5'TGAC G GATCC C CTACAAG G GAAG G CCAG G GAAq-i-T- 
TC-I-I-CAGAG, corresponding to nucleotides 2108-2141 
of the HIVq HXB2 genome with a 5' BamHI site added; 
antisense primer= 5'TGACAAGCTTGGCACTAC-i-lqq-AT- 
GTCACTATTATCTTGT, corresponding to nucleotides 
4981-5011 with an 5' Hindlll site). The purified and re- 
stricted PCR fragment was inserted into a pDS56/RBSII 
vector (pQE4, Diagen; StOber et al., 1990). After transfor- 
mation into E. col/strain M4022, expression was induced 
with 2 mM IPTG. Cells were harvested and lysed in sam- 
ple buffer, and proteins were Separated by SDS-PAGE 
(Laemmli, 1970). Processing of pol was analyzed by Im- 
mune-blot with a rabbit serum against HIV-1 reverse tran- 
scriptase (Towbin et aL, 1979). 
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Construction of HIV-1 HXB2 virus containing mutant 
proteinase 
Proviral genome containing plasmid was transfected 
into Cos cells by the Lipofectin method (10 #g DNA/106 
cells) following the manufacturer's instructions (Gibco 
BRL). Supernatants of transfected Cos were used to in- 
fect MT-2 cells. The resulting virus-containing superna- 
tants were passaged again on MT-2 and subsequently 
used to assay for sensitivity to Ro 31-8959. MT-2 cells 
were infected for 1 hr with virus-containi.ng supernatant, 
washed once, and aliquoted on microtiter plates in me- 
dium with inhibitor. After about 4 days when control cul- 
tures showed widespread syncytia formation, the super- 
natants were harvested and analyzed for virus growth by 
p24 ELISA (DuPont). Sensitivity of the HXB2 virus with 
the double mutation (Va148/Leu90) to proteinase inhibitor 
was assayed on PBMC following the protocol of the 
ACTG/DoD PBMC consensus assay (Japour etaL, 1993). 
RESULTS 
Selection of HIV-1 GB8 resistant to proteinase 
inhibitor 
HIV-1 GB8 was passaged on CEM cells, a human T- 
lymphoblastoid cell line, in the continuous presence of 
the proteinase inhibitor Ro 31-8959 as described (Craig 
etaL, 1993b). Selection was started at 10 nMwhich corre- 
sponds approximately to 1.5 X 50% inhibitory concentra- 
tion (IC~o) in this particular cell-virus system. When 
significant virus growth had occurred as judged by 
microscopic examination of the infected culture, i.e., ob- 
servation of extensive cell clumping and syncitia forma- 
tion, cell-free supematant was harvested and used for 
de novo infection of CEM cells. Selection was continued 
in parallel cultures with either the previous inhibitor con- 
centration maintained or at twice that concentration. In- 
hibitor concentrations were raised whenever growth at 
the previously highest concentration had occurred, other- 
wise selection was continued at the same concentration. 
Sequence analysis of the proteinase of resistant virus 
We initially sequenced 10 individual clones of the pas- 
sage 11 (P11) viral proteinase following its PCR amplifi- 
cation from total DNA of infected CEM cells and cloning 
into pBluescript vector. Since this particular HIV-1 strain 
had not been molecularly characterized before, we se- 
quenced for comparison 11 wild-type proteinase clones 
which had been isolated by the same procedure from 
HIV-1 GB8-infected cells without previous passages in 
the presence of Ro 31-8959. The deduced protein se- 
quences were aligned and compared for amino acid ex- 
changes (Fig. 1). Two striking differences between wt 
and P l l  virus proteinases were noted, i.e., a glycine to 
valine exchange at peptide position 48 and a leucine to 
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RO31 . . . . . . . . . . . .  t . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
RO32 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  V - -  
RO33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  V - -  
RO34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  v - -  
RO35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  %"-'- 
RO36 . . . . . . . . . . . . .  - . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  v - -  
RO37 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  V - -  
RO38 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  v - -  
RO39 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  V - -  
RO41 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . .  v - -  
Wt l7  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l6  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
Wt l5  . . . . . . . . . . .  i . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l4  . . . . . . . . . . .  i . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
Wt l3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  s . . . . . . . . . . . . .  
Wt l l  - - -~  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
Wt l0  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
Wt09  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . . . . . . . . . . .  
Wt08  . . . . . . . . .  1 . . . . . . . . . . . . . . . . . . . . . . . . . .  s . . . . . . . . . . . . .  
Wt07  . . . . . . . . . . .  i . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt -C  PQITLWQRPV VT IK IGGQLK EALLDTGADD TVLEEMNLPG RWKPKMI~GI  
Ro-C  PQITLVQRPV VT IK IGGQLK EALLDTGADD TVLEE INLPG RWKPKMIXGI  
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Ro31 . . . . . .  r r  . . . .  v l  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i . . . . .  
Ro32 . . . . . .  r . . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
RO33 . . . . . .  rh  . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m - .  . . . . . . .  
RO34 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m - .  . . . . . . .  
RO35 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
RO36 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m - - - .  . . . . .  
Ro37 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
Ro38 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
Ro39 . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
RO41 - - i - - - r  . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . .  
Wt l7  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l6  . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l5  . . . . . .  r . . . . .  v . . . . . . . . . . . . . . . . . . . . . . . . . . . .  hv  . . . . . .  
Wt l4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt l2  . . . . . .  r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wi l l  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  m . . . . . . . . . . . . . . .  
Wt l0  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt09  . . . . . . . . . . . . . . .  - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt08  . . . . . .  r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt07  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Wt -C  CGF IKVKQYD QILVE ICGHK A IGTVLVGPT PV Iq I IGRNL~ TQLGCTLNF 
Ro-C  GGFIK~XRQYD QIVVEICGHK A IGTVLVGPT PV Iq I IGRNL I I  TQLGCTLNF 
FIG. 1. Comparison of proteinases from HIV-1 GB8 wild-type virus 
and virus selected for resistance to Ro 31-8959 (passage 11). Protein- 
ase gene was amplified by POR from proviral DNA and inserted into 
pBluescript, and the sequences from individual clones were obtained. 
An alignment of sequences from 11 wild-type (wt07-17) and 10 passage 
11-genes (Ro31-39, 41) is shown. - indicates that all sequences hare 
the same residue at the given position; deviations from the consensus 
are indicated by lower case letters. The one-letter code for amino acids 
is used. Wt-C and Ro-C are the consensus sequences of either all wt 
clones or all P11 clones. Positions which are considered to be relevant 
for resistance are underlined by a dot, positions 48 and 90 are addition- 
ally highlighted by bold lettering. 
methione exchange at position 90. The two amino acid 
exchanges are both caused by base transversions. The 
Gly48 --* Val exchange is consequent to a G -* T mutation 
whereas a T -* A mutation underlies the Leu90 ~ Met 
exchange. In addition we observed sequence heteroge- 
neities at several other positions (i.e., positions 12, 36, 
37, 57, 63) in the wt sequences where the selected virus 
proteinase displayed a more homogenous pattern. 
Recently, five domains in the HIV-1 proteinase have 
been defined which are highly conserved among all 
known virus isolates (Fontenot et al., 1992). Gly48 bor- 
ders the conserved domain III and is part of the GGIGGFI 
motif which is found in HIV-1, HIV-2, and SlV, whereas 
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FIG. 2. Structural model of HIV-1 proteinase with inhibitor Ro 31-8959 
showing mutations of G48V and L90M as solid spheres. 
keu90 borders the conserved domain IV and is also con- 
served among the three primate immunodeficiency vi- 
ruses as well as in other retroviral proteinases. A struc- 
tural model of the HIV-1 proteinase based on X-ray analy- 
sis places the G48 into the flexible "flap" covering the 
substrate binding site with the bulky aliphatic side chain 
of the mutant valine protruding into the interior of the 
binding site (Fig. 2). The Leu90 is localized to the core 
of the proteinase with no obvious contact o enzyme- 
bound substrate or inhibitor (Wlodawer and Erickson, 
1993). 
We also analyzed the sequence of virus proteinase at 
a later point of selection (passage 14, growth in 640 nM 
Ro 31-8959). However, no additional exchanges in the 
peptide sequence were observed (data not shown). Of 
10 sequences of the P11-selected virus 1 had maintained 
the genotype of the wt proteinase sequence (Fig. 1, 
Ro31). This would indicate that here is still a heteroge- 
nous virus population with a minority of wt virus although 
we cannot rigorously exclude an accidental PCR contam- 
inant. 
It was of interest o determine the order of appearance 
of the mutations that led to the resistant phenotype. We 
thus obtained the proteinase sequence at the earlier pas- 
sages 7 and 8 from virus grown at 40 and 80 nM Ro 31- 
8959, respectively (Fig. 3). P7 virus still showed the wt 
sequence at position Gly48 and Leu90. However, earlier 
heterogeneities in the wt sequences at positions 12(Iso/ 
Thr), 36(Met/lie), 37(Ser/Asn), 57(Lys/Arg), and 63(Leu/ 
Val) had resolved into a homogeneous pattern in P7 virus, 
i.e., Thr12, Ile36, Ash37, Arg57, and Va163, respectively. 
The changed patterns at positions 36, 57, and 63 were 
statistically significant (P = 0.009, 0.003, and 0.002, re- 
spectively), while those at positions 12 and 37 were not 
(P = 0.276 and 0.262, respectively). Moreover, no single 
wt sequence had all residues at positions 36, 57, and 63 
as found in the consensus P7 sequence. This suggests 
that during passages 1 to 7 a rare wt sequence had 
become the predominant genotype of the P7 viral popula- 
tion or that selection of spontaneously arising mutants 
at these positions had occurred. Further selection at a 
higher concentration of Ro 31-8959 led to the appearance 
of the Va148 mutant in P8 virus on the genotypic back- 
ground of the P7 virus and subsequently at a later time 
point to the appearance of the Va148/Met90 double mu- 
tant as found in the passage 11 virus. 
Comparison of cleavage site sequences 
Mutations in the proteinase substrate-binding site 
could conceivably require compensating amino acid ex- 
changes at or surrounding the substrate cleavage sites. 
Thus, we determined the peptide sequences within the 
p55 gag precursor and at the N- and C-termini of the 
proteinase itself. These cleavage sites include the Tyr-  
Pro (p17/p24), Leu-Ala (p24/X), Met -Met  (X/p9), and 
Phe-Pro (p15/proteinase and proteinase/R-I-) scissile 
bonds. No consistent differences between wt virus and 
virus selected for resistance to Ro 31-8959 were ob- 
served (data not shown). We conclude that no such com- 
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P7 /9  . . . . . . . . . . . . .  r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /8  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  - . . . . . . . . . . . . . . . . .  
P7 /7  . . . . . . . . .  1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /6  . . . . . . . . .  1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 / l l  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 -C  PQITLWQRPV VT IK IGGQLK EALLDTGADD TVLEE INLPG RWKPKMI@GI  
PS / I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  v - -  
P8 /2  - - t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  v - -  
P8 /3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  v - -  
P8 /4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  v- -  
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P7/9  . . . . . . . . . . . . . . . . . . . . . . . .  1 . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /8  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /7  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 /6  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  a - - -  
P7 /2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 / I I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P7 -C  GGF IKVRQYD QIVVE ICGHK A IGTVLVGPT PVNI IGRNLL  TQLGCTLNF 
P8 / I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P8 /2  . . . . . . . . . . . . . . . . . . . . . .  P . . . . . . . . . . . . . . . . . . . . . . . . . .  
P8 /3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
P8 /4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
FiG. 3. Comparison of proteinases from HIV-1 GB8 passage 7 (P7) 
and passage 8 (P8). Sequences were obtained as described in the 
legend to Fig. 1. - indicates that all sequences hare the same residue 
at the given position; deviations from the consensus are indicated by 
lowercase letters. The one-letter code for amino acids is used. P7-C 
is the consensus equence of the passage 7 sequences. Positions 
which are considered to be relevant for resistance are underlined by 
a dot; positions 48 and 90 are additionally highlighted by bold lettering. 
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FIG. 4. (A) Growth kinetics of HIV-1 GB8 wild-type and P11 virus. CEM cells were infected with virus-containing culture sup rnatant, washed, and 
resuspended at 2.5 x 105/ml in fresh medium. Aliquots of the supernatant were removed at Days 2 to 6 postinfection and p24 antigen concentration 
was determined in an ELISA assay. (B) Sensitivity of HIV-1 GB8 wild-type and Pll to Ro 31-8959. Cells and infection were as described in (A). 
Inhibitor was added to 1800, 600, 200, 67, 22, 7.5, and 2.5 nM final concentration. When extensive synoitia formation in the control culture had 
developed, culture supernatants were harvested and p24 antigen was determined. Content. of p24 in the supernatant is expressed as percentage 
of a control infected culture without inhibitor. 
pensating exchanges are required for the mutant protein- 
ase to process the p55 gag and p160 gag-po l  precursor. 
Characterization of the P11 virus 
We compared wt and P1 1 virus with respect to growth 
in CEM cells and sensitivity to proteinase inhibitor. In 
acute infection, growth of resistant virus was as rapid as 
wt virus reaching the same level of p24 antigen in the 
culture supernatant within 4 to 5 days (Fig. 4A). Inhibition 
of virus growth by Ro 31-8959 was likewise assayed in 
acute infections of CEM cells. For wt virus an 105o of 7 nM 
and an lOgo of 16 nM was determined. The corresponding 
values for P11 virus were 250 nM and 1500 nM, respec- 
tively (Fig. 4B). Thus, drug selection yielded a virus with 
a 30- to 100-fold decrease in sensitivity to proteinase 
inhibitor without any gross defects in viability. To assess 
the stability of the genotype of resistant virus we grew 
P11 virus for 20 passages in the absence of Ro 31-8959. 
Sequencing of the proteinase gene of such virus re- 
vealed no difference to P11 virus demonstrating the sta- 
bility of the mutant genotype without selection pressure 
(data not shown). 
Mutagenesis of HIV-1 proteinase 
Laboratory strains of HIV-1 grown in either T-cell lines 
or monocytic cells are highly susceptible to the inhibitory 
activity of Ro 31-8959. The IC~o in acute infection models 
is usually less than 5 nM. To obtain more definite evi- 
dence that the Gly48 -* Val and Leu90 --, Met exchanges 
lead to a resistant phenotype both mutations were intro- 
duced either alone or in combination into the HIV-1 HXB2 
proteinase by PCR-directed mutagenesis. The mutated 
proteinase gene was inserted into the HXB2 pc /gene  
and cloned into E. coil vector pQE4 which allows expres- 
sion under the control of the lacl repressor (St(Jber et 
aL, 1990). After induction of transformed bacteria, the 
activities of the mutated proteinases were monitored by 
immunobiot analysis for processing of the reverse tran- 
scriptase precursor to p66/p51 (Fig. 5). Cleavage of the 
pol gene product was observed for all pc~ constructs 
containing either wild-type or mutated proteinases prov- 
ing that both Val48 and Met90 mutations are compatible 
with enzyme activity. However, examination of pro- 
cessing kinetics indicated consistent differences in the 
time course of p66/p51 appearance. Cleavage by the 
Va148 proteinase was reproducibly delayed when com- 
pared to the wt, Met90, or double mutant enzyme. Pro- 
cessing was incomplete at early times postinduction and 
reached wt levels only after 3 to 4 hr. Moreover, pro- 
(:essing of p66 to p51 seemed to be less efficient in both 
single mutants. This would point to quantitative differ- 
1.5 h 
N 
2.5h  4h  
j ~ ~ p66 ~ -,~-p51 
Fte. 5. Activity of mutant proteinase in E. coil The pol open reading 
frame of HIV-1 HXB2 containing a wild-type proteinase (lanes 1), a 
G48V mutant (lanes 2), a L90M mutant (lanes 3), or a G46V/Lg0M 
mutant proteinase (lanes 4) was expressed in E. col~ as described 
under Material and Methods. Cells were harvested at the indicated 
times after induction; lysed proteins were resolved by SDS-PAGE. 
Processing of the pol gene product to p66/p51 was analyzed by immu- 
noblot with an antireverse transcriptase rabbit serum. As a control 
for processing by the viral proteinase a pol ORF with an inactivated 
proteinase (D25A) was run in parallel (lanes C). 
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TABLE 1 
SENSITIVITY OF HIV-1 HXB2 WILD-TYPE VIRUS AND PROTEINASE 
MUTANTS TO RO 31-8959 
Vi ru s I Cso a I C9o a 
HXB2 wt 1.7 nM MT-2 8.9 nM MT-2 
6.0 nM PBMC n.d. 
HXB2 G48-V 13.5 nM MT-2 20.0 nM MT-2 
HXB2 Lg0-M 5.7 nM MT-2 15.1 nM MT-2 
HXB2 G48V + Lg0M 120.0 nM PBMC n.d. 
Note. Virus was prepared by transfection of Cos cells with plasmids 
Containing proviral genomes of HIV-1 HXB2 with either wild-type or 
mutant proteinase and cocultivation with MT-2 cells. Infection, inhibitor 
treatment, and p24 assay were as described in the legend to Fig. 4 
except hat MT-2 cells were used. Sensitivity ofthe double mutant virus 
was assayed on PBMC following the ACTG consensus protocol. 
a IOs0/9o, 50/90% inhibitory concentration of Ro 31-8959; n.d., not de- 
termined. 
ences in proteinase activity between wt, single mutants, 
and double mutants, tt should be noticed that these dif- 
ferences were uniform among a number of individual 
clones tested for each proteinase mutant. 
Sensitivity of mutant HXB2 virus to Ro 31-8959 
Infectious HIV-1 HXB2 proviral genomes containing 
either the single mutant proteinases Gly48 -* Val and 
Leu90 ~ Met or the double mutant proteinase were con- 
structed by directed mutagenesis and virus was recov- 
ered via transfection and passage on MT-2 cells. Sensi- 
tivity to Ro 31-8959 was assayed in acute infections of 
either MT-2 cells or stimulated PBMC by measuring the 
p24 level in the culture supernatants. Introduction of ei- 
ther mutation at position 48 or at position 90 led to a 
small but reproducible increase in IO5o/9 o, which supports 
their proposed significance in the evolution of resistance 
to Ro 31-8959. The values for IC5o and IC~o derived from 
these titrations are shown in Table 1. The single muta- 
tions raised the IC5o for Ro 31-8959 by 3.4- and 8-fold, 
respectively, with a concomitant increase in IC9o. Growth 
of the double mutant virus in the presence of inhibitor 
yielded an IC~o value of 120 nM which represents a ca. 
20-fold increase over the corresponding value for the 
wild-type virus in the PBMC assay system. These results 
indicate that the presence of both mutations in the pro- 
teinase gene is necessary to give a Ro 31-8959 resis- 
tance phenotype. 
DISCUSSION 
In this study we present a phenotypic and genotypic 
description of an HIV-1 variant selected for resistance to 
proteinase inhibitor Ro 31-8959. Furthermore, we provide 
support for the proposed resistance genotype by directed 
mutagenesis of a wt HIV-1 HXB2 proteinase gene. Evolu- 
tion of resistance in the case of the HIV-1 GB8 strain 
initially seemed to involve a selection of a rare, preex- 
isting wt genotype. This led to a virus population with a 
homogeneous amino acid distribution at positions 12, 36, 
57, and 63. A subpopulation with an a priori decreased 
sensitivity to Ro 31-8959 may thus exist in the previously 
nonselected HIV-1 GB8 wild-type virus population. How- 
ever, titration of the P7 virus for its sensitivity to Ro 31- 
8959 gave variable values for the lOgo, which on an aver- 
age were only slightly higher than for the wt virus (data 
not shown-). The first de novo mutation at position 48 
occurred within the background of this selected wt se- 
quence followed subsequently by the second de novo 
mutation at position 90 to give the fully resistant virus. 
The importance of the positions 48 and 90 for the resis- 
tance phenotype could be confirmed by specific muta- 
genesis of the HIV-1 HXB2 proteinase. Either single mu- 
tation by itself resulted in a virus which showed only a 
modest reduction in its sensitivity to Ro 31-8959 when 
assayed in an acute infection experiment. However, com- 
bining the Va148 and Leu90 exchanges into one wt HXB2 
proteinase gave rise to a virus which was markedly resis- 
tant to the inhibitor. The primary significance of these 
positions for development of resistance has been re- 
cently confirmed when proteinase sequences were ob- 
tained from proviral DNA of PBMC from patients after 
prolonged treatment with Ro 31-8959. In a number of 
integrated virus genomes proteinase genes with Val at 
position 48 and Leu at position 90 were observed (H. 
Jacobsen, unpublished results). The importance of posi- 
tions 12, 36, 57, and 63 for the selection of the resistant 
HIV-1 GB8 remains unclear. Conceivably, residues at 
these positions could compensate for detrimental effects 
of the Va148/Leu90 mutations on proteinase activity and 
fitness of the virus. An ongoing biochemical analysis of 
single and double mutant proteinase in an in vitro assay 
will help to clarify the functional consequences of these 
mutations. 
Molecular modeling based on structural data from the 
HIV-1 proteinase/Ro 31-8959 complex suggests that the 
Gly to Val exchange at position 48 may directly interfere 
with binding of the inhibitor to a substrate-binding site 
by steric interference of the Val side chain. However, the 
Leu90 ~ Met exchange alone also decreases sensitivity 
of the proteinase to the inhibitor as demonstrated by the 
mutagenesis of the HXB2 proteinase which led to a three- 
to fourfold increase in IO5o. Furthermore, a selection of 
HIV-2 Ben in the presence of Ro 31-8959 yielded a virus 
with a Leu90 --* Met exchange as sole mutation which 
grew at 70 nM Ro 31-8959 (data not shown). Clearly, 
more structural data are necessary to define the precise 
contribution of Met90 to resistance. Recently a Va182 to 
AIR exchange has been described as being critical for 
resistance to C-2 symmetrical proteinase inhibitors with- 
out diminishing the activity of Ro 31-8959 (Otto et aL, 
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1993). We have previously prepared a Val82 --* Phe mu- 
tant in HXB2 proteinase and found that the resulting virus 
grew only poorly with unaltered sensitivity to Ro 31-8959. 
Further selection experiments, possibly with other HIV-1 
strains, may reveal additional mutations in the proteinase 
gene which reduce its sensitivity to Ro 31-8959. 
Resistance to reverse transcriptase inhibitors has be- 
come a major problem in their clinical use. Careful selec- 
tion of dosage, the alternating use of different inhibitors 
which are not subject to cross resistance, or combination 
therapy may be ways to prevent or delay onset of viral 
resistance. In the case of Re 31-8959, clinical trials of 
phase II/lll are underway and analysis of clinical isolates 
for changes in resistance to inhibitor will be of major 
importance. Combination of reverse transcriptase and 
proteinase inhibitors may turn out to be useful therapeu- 
tic regiments since cell culture studies indicate syner- 
gistic enhancement of antiviral activities (Craig et al., 
1993a). Furthermore, the existing data on resistance to 
proteinase inhibitors, albeit rather limited, suggest that 
combination of structurally different inhibitors may avoid 
cross resistance and thus increase their therapeutic po- 
tential. 
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